Prostate Adenocarcinoma Clinical Trials in New York, New York
8 recruitingNew York, New York
Showing 1–8 of 8 trials
Recruiting
Phase 3
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
Prostate CancerProstate Adenocarcinoma
Curium US LLC439 enrolled43 locationsNCT06235151
Recruiting
Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Stage IVB Prostate Cancer AJCC v8Metastatic Prostate AdenocarcinomaCastration-Sensitive Prostate Carcinoma
Alliance for Clinical Trials in Oncology1,260 enrolled177 locationsNCT06931340
Recruiting
Phase 3
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IVA Prostate Cancer AJCC v8
NRG Oncology1,209 enrolled398 locationsNCT05946213
Recruiting
Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Metastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8Biochemically Recurrent Prostate Carcinoma+1 more
ECOG-ACRIN Cancer Research Group804 enrolled303 locationsNCT04423211
Recruiting
Phase 2
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
Icahn School of Medicine at Mount Sinai120 enrolled1 locationNCT07285057
Recruiting
Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Stage III Prostate Cancer AJCC v8Prostate AdenocarcinomaStage I Prostate Cancer AJCC v8+2 more
NRG Oncology586 enrolled347 locationsNCT04134260
Recruiting
Phase 3
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
Prostate Adenocarcinoma
NRG Oncology2,050 enrolled575 locationsNCT05050084
Recruiting
ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Prostate CancerProstate Cancer MetastaticProstate Adenocarcinoma+1 more
Duke University120 enrolled3 locationsNCT06141993